| __timestamp | Incyte Corporation | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 5496000 |
| Thursday, January 1, 2015 | 196614000 | 9786000 |
| Friday, January 1, 2016 | 303251000 | 6792000 |
| Sunday, January 1, 2017 | 366406000 | 7313000 |
| Monday, January 1, 2018 | 434407000 | 8382000 |
| Tuesday, January 1, 2019 | 468711000 | 10803000 |
| Wednesday, January 1, 2020 | 516922000 | 12944000 |
| Friday, January 1, 2021 | 739560000 | 21967000 |
| Saturday, January 1, 2022 | 1002140000 | 32810000 |
| Sunday, January 1, 2023 | 1161300000 | 46542000 |
| Monday, January 1, 2024 | 1242157000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Incyte Corporation and Xenon Pharmaceuticals Inc. have shown contrasting approaches. Incyte's SG&A expenses surged by over 600%, from approximately $166 million in 2014 to $1.16 billion in 2023. This reflects their aggressive expansion and investment in operational capabilities. Conversely, Xenon Pharmaceuticals maintained a more conservative growth, with SG&A costs increasing by around 750%, from $5.5 million to $46.5 million over the same period. While Incyte's larger scale allows for higher absolute spending, Xenon's leaner approach might suggest a more efficient cost management strategy. As the industry evolves, these trends highlight the strategic choices companies make in balancing growth with cost efficiency.
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Incyte Corporation vs Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Incyte Corporation and ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Merus N.V.
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.